NEW YORK – Lucira Health, a startup formerly known as Diassess, announced today it has closed a $15 million Series B equity financing round.
The Emeryville, California-based developer of instrument-free, molecular diagnostics for infectious disease testing intends to use the funds to finance regulatory clearances and early commercialization.
The funding was led by Seraph Group with participation from Eclipse Ventures, DCVC (Data Collective), Y Combinator, Sunstone Management, and ShangBay Capital, the firm said in a statement.
Lucira Health is developing molecular diagnostic tools for infectious diseases. It has been developing STI testing, and last year it was awarded funding of up to $21.9 million from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) for its flu test development.
The firm has developed a disposable, battery-operated device for flu A/B testing, and plans for the commercial launch of a professional-use product, followed by a consumer-use product that will pair with a smartphone app and connect a user to treatment options.
"With the upcoming commercialization of the first fully disposable molecular influenza test, we are excited to offer products that fit the growing healthcare delivery workflow of bringing evidence-based decision making to the patient bedside," said Erik Engelson, Lucira Health's CEO.